A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.
By C. Chesnut, S. Silverman, K. Andriano, H. Genant, A. Gimona, S. T. Harris, D. Kiel, M. LeBoff, M. Maricic, P. Miller and 5 more. American Journal of Medicine, 2000
1,084 citations recorded by the source corpus.
Subfields: Cellular and Molecular Neuroscience, Orthopedics and Sports Medicine, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/b05f6e717772958e59575400a48dd62811c32636
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Orthopedics and Sports Medicine
Citations in the corpus
- Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. (2005, background): “Other antiresorptive agents with proven antifracture efficacy include long-term estrogen therapy (27), raloxifene (28), and nasal calcitonin (29).”
- Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards (2011, neutral): “Calcitonin Chesnut [83] 200 IU/day, intranasal −10 Strontium ranelate Meunier [84] 2 g/day +8 −12 Bruyère [85] −11”
- The clinician’s guide to prevention and treatment of osteoporosis (2022, background): “Calcitonin reduces vertebral fracture occurrence by about 30% in those with prior vertebral fractures but does not reduce the risk of non-vertebral fractures [200].”